High‐Throughput Screening for Prescribing Cascades Among Real‐World Angiotensin‐ <scp>II</scp> Receptor Blockers ( <scp>ARBs</scp> ) Initiators
The identified PC signals reflected known and possibly under-recognized ARB adverse events in this Medicare cohort. These hypothesis-generating findings require further investigation to determine the extent and impact of these PCs on patient outcomes.
Authors
- M.-C. Calvet
- Steven M. Smith (ORCID: https://orcid.org/0000-0002-0201-839X)
- Asinamai Ndai (ORCID: https://orcid.org/0000-0002-2517-3915)
- Shailina Keshwani (ORCID: https://orcid.org/0000-0002-9961-2511)
- Stephan Schmidt (ORCID: https://orcid.org/0000-0002-4998-1167)
- Carl J. Pepine (ORCID: https://orcid.org/0000-0002-6011-681X)
- Scott Martin Vouri (ORCID: https://orcid.org/0000-0002-0411-2160)
- Earl J. Morris (ORCID: https://orcid.org/0000-0002-6092-8906)
- Jaeyoung Choi (ORCID: https://orcid.org/0000-0001-8264-1482)
- Kayla Smith (ORCID: https://orcid.org/0009-0001-7308-5397)
- Michael Luvera
- Tanner Beachy
Institutions
- Center for Drug Evaluation and Research (US)
- Pfizer (United States) (US)
- University of Florida Health (US)
- University of Florida (US)
- Florida College (US)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2025-10-21
- DOI
- https://doi.org/10.1002/phar.70068
- Citations
- 1
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.39